Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
+44 1223 790975
ISSN: 2471-9552
+44 1223 790975
Gary J Schiller
Tanzania
Review Article
Clinical Implications of Anti-CD19 Chimeric Antigen Receptors (CAR) T Cell Therapy in Acute Lymphoblastic Leukemia (ALL)
Author(s): Ali R Jazirehi, Tam N M Dinh, Zena Taraporewalla, Jahzeel L Paguntalan and Gary J SchillerAli R Jazirehi, Tam N M Dinh, Zena Taraporewalla, Jahzeel L Paguntalan and Gary J Schiller
Acute Lymphoblastic Leukemia (ALL) is a cancer of white blood cells that is most prevalent among young children. Several environmental and genetic factors contribute to the occurrence of ALL, including radiation exposure, ethnicity, gender, and other genetic traits. Traditional treatment options include chemotherapy, radiation, and bone marrow transplant. More recently, a form of antibody-mediated immunotherapy using genetically engineered chimeric antigen receptor (CAR) T-cells has been used in several clinical trials with encouraging results. CAR T-cells allow for highly targeted treatment by inducing activation of the modified T-cells and stimulating an apoptotic response in target B-cells upon ligation with a given antigen target. Typically, modified CAR T-cells are capable of specific recognition of the B-cell surface marker CD19, a universally expressed oncogenic antigen found i.. View More»
DOI:
10.4172/2471-9552.1000142